There have been several noteworthy developments
in the drug space
recently, which will likely have a material impact on the companies in this sector and the markets they serve. Companies mentioned in this review include Pfizer Inc
. (PFE), AstraZeneca
(AZN), Merck & Co.
(MRK), AbbVie Inc
. (ABBV), and Eli Lilly
As the U.S. bull market
for equities marches toward a sixth straight year, major benchmarks
such as the S&P 500
and Dow Jones Industrials
have clawed their ways to new highs
. However, the numbers alone don’t tell the whole story. The Dogs of the Dow strategy
, unsurprisingly, is also benefitting from the upswing, advancing every month with the exception of January. Although August found the pack lagging the gains posted by the 30 Dow Industrials as a whole, year-to-date performance has maintained a relatively comfortable lead. Merck
logged the biggest gains last month, but Intel’s stock has outrun the Dogs (and the rest of the Dow components, for that matter) by a sizable margin so far this year.
The end of the third quarter is rapidly approaching, so we will preview
the upcoming earnings season
for the restaurant industry
. We will also take a look at a large proposed acquisition, the impact of rising wages and food costs, and a recent supplier issue.
As the anti-GMO
(genetically modified organisms) movement
begins to rack up some victories, organic foods
are enjoying greater popularity.
There have been many noteworthy developments
in the technology space
recently. Some of these will likely have a material impact on the companies in the sector and the markets they serve. Companies featured here include Amazon.com
, and Compuware
The Office of the Comptroller of the Currency
, or OCC, has played a key role in the creation of the national banking system and in restoring the industry’s health during times of financial crisis. It continues to monitor the condition of the banking sector, and provides investors with a wealth of information regarding the industry.
has come and gone and the results were fairly clear: Most retailers continue to deal with the ill effects of a still-sluggish economic environment. Although there were a few that persevered and were able to post better-than-expected results, the majority operating in this space continued to struggle on a year-over-year basis.
The Federal Reserve
is close to ending its massive bond buying program. The next step is to normalize interest rates. But what is normal?
There have been several noteworthy developments in the drug space recently, which will likely have a material impact on the companies in this sector and the markets they serve. Companies mentioned in this review include Pfizer Inc.
(PFE), Merck & Co.
(MRK), Valeant Pharmaceuticals International Inc.
(VRX), and Allergan Inc.
Cloud-based electronic health records
have emerged as a popular choice among practitioners. Should investors
get behind this technology
or is this merely the latest fleeting craze?